Tazarotene Inhibitor CAS No. 118292-40-3

Cat. No.	Name	Size	Price	Add Cart
KI0782	Tazarotene	10 mg	$154
KI0782	Tazarotene	50 mg	$496

Chemical Characteristic

Product Name	Tazarotene
Synonyms	AGN 190168
CAS No.	118292-40-3
Molecular Weight	351.46
Formula	C₂₁H₂₁NO₂S
Chemical Structure

Biological activities

Tazarotene is a retinoic acid receptor-specific retinoid. Tazarotene is the first topical retinoid to become available for the treatment of psoriasis. Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. Tazarotene also upregulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect.^[1] Tazarotene induces hairless mouse hyperplasia with an ED50 of 100 nM. ^[2] In vitro, tazarotene induces a concentration-dependent increase of RAR-β and bax associated with a greater rate of apoptosis and growth inhibition in basaloid tumor cells compared with squamous tumor cells. Tazarotene also induces basal cell carcinomas (BCC) regression possibly by synergistic RAR-β-dependent anti-proliferative and proapoptotic pathways. Tazarotene inhibits cell growth more in C5N than in B9 cells. ^[3] In vivo, topical application of tazarotene induces TIG-2 expression in Psoriatic Lesions. ^[4] TIG-3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. ^[5]

References

[1] Duvic M, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997, 37(2 Pt 3): S18-24. [2] Thacher SM, et al. Receptor specificity of retinoid-induced epidermal hyperplasia: effect of RXR-selective agonists and correlation with topical irritation. J Pharmacol Exp Ther. 1997, 282(2): 528-534. 閵嗏偓閵嗏偓 [3] Orlandi A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol. 2004, 122(4): 1037-1041. 閵嗏偓 [4] Nagpal S, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997, 109(1): 91-95. 閵嗏偓閵嗏偓 [5] Duvic M, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003, 121(4): 902-909. 閵嗏偓

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services

Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services

Biochemical Products

Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR

KareBay^TM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852

Telephone

: 732-823-1545

Fax

: 732-823-1349

product@karebaybio.com
service@karebaybio.com
support@karebaybio.com